The pattern of P53 and P21(WAF1/CIP1) immunoreactivity in non-Hodgkin's lymphomas predicts P53 gene status

Diagnostic Molecular Pathology

Volumn 6, Issue 4, 1997, Pages 222-228

  Mansukhani, Mahesh M ^a   Osborne, Barbara M ^a   Zhong, Jingyao ^a   Matsushima, Anne Y ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

Immunohistochemistry; Non Hodgkin's lymphoma; p21 waf1 cip1 sdi1; p53 tumor suppressor gene; PCR SSCP

Indexed keywords

PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA;

ARTICLE; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; DNA SEQUENCE; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MUTATION;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, NEOPLASM; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031284881     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-199708000-00006     Document Type: Article

References (35)

1. Adamson DJ, Thompson WD, Dawson AA, Bennett B, Haites NE. P53 mutation and expression in lymphoma. Br J Cancer 1995;72: 150-54.
2. Akama Y, Yasui W, Kuniyasu H, et al. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines. Jpn J Cancer Res 1996;87:824-30.
3. Balint E, Reisman D. Increased rate of transcription contributes to elevated expression of the mutant p53 gene in Burkitt's lymphoma cells. Cancer Res 1996;56:1648-53.
4. Barbareschi M, Caffo O, Doglioni C, et al. P21/WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996;74:208-15.
5. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 1993;143:845-56.
6. Cesarman E, Liu YF, Knowles DM. The MDM2 oncogene is rarely amplified in human lymphoid tumors and does not correlate with p53 gene expression. Int J Cancer 1994;56:457-58.
7. Clayman GL, Liu TJ, Overholt SM, Mobley SR, Wang M, Janot F, Goepfert H. Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/ CIP1 (p21). Arch Otolaryngol Head Neck Surg 1996;122:489-93.
8. el-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
9. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84.
10. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. P53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147:884-88.
11. Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996;16:4961-71.
12. Gaidano G, Ballerini P, Gong JZ, et al. P53 mutations in human lymphoid malignancies: association with Burkitt's lymphoma and chronic lymphocytic leukemia. Proc Nat Acad Sci USA 1991;88 (12):5413-18.
13. Gong JZ, Shou H, Hu Z, Schulman P, Vinceguerra V, Broome JD, Koduru P. Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia. Hematol Pathol 1995;9:171-77.
14. Hirano Y, Yamato K, Tsuchida N. A temperature sensitive mutant of the human p53, Val138, arrests rat cell growth without induced expression of cip1/waf1/sdi1 after temperature shift-down. Oncogene 1995;10:1879-85.
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
16. Kawamata N, Miller C, Levy V, Shintaku IP, Koeffler HP, Said JW. MDM-2 oncogene expression in non-Hodgkin's lymphomas. Diagn Mol Pathol 1996;5:33-38.
17. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-56.
18. Li Y, Jenkins CW, Nichols MA, Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994;9:2261-68.
19. Maestro R, Gloghini A, Doglioni C, et al. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 1995;85:3239-46.
20. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996;56: 2649-54.
21. Martinez JC, Mateo M, Sanchez-Beato M, et al. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J Pathol 1995;177:27-34.
22. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Post thymic T-cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 1994;144: 573-84.
23. Matsushita K, Kobayashi S, Kato M, Itoh Y, Okuyama K, Sakiyama S, Isono K. Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. Int J Cancer 1996;69:359-64.
24. Nakamura H, Said JW, Miller CW, Koeffler HP. Mutation and protein expression of p53 in AIDS-related lymphomas. Blood 1993;82:920-26.
25. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 1992;358:80-83.
26. Papadaki H, Kounelis S, Kapadia SB, Bakker A, Swalsky PA, Finkelstein SD. Relationship of p53 gene alterations with tumor progression and recurrence in olfactory neuroblastoma. Am J Surg Pathol 1996;20:715-21.
27. Petrocelli T, Poon R, Drucker DJ, Slingerland JM, Rosen CF. UVB radiation induces p21Cip1/WAF1 and mediates G1 and S phase checkpoints. Oncogene 1996;12:1387-96.
28. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996;10:1945-52.
29. Roy B, Beamon J, Balint E, Reisman D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 1994;14:7805-15.
30. Said JW, Barrera R, Shintaku IP, Nakamura H, Koeffler P. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol 1992;141:1343-48.
31. Shiohara M, el-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84: 3781-84.
32. Slebos RJ, Baas IO, Clement M, et al. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 1996;74:165-71.
33. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42:858-68.
34. Zedenius J, Larsson C, Wallin G, et al. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. Thyroid 1996; 6:1-9.
35. Zeng YX, el-Deiry WS. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 1996;12:1557-64.